Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization.

Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, De Beaufort C, De Waele K, Scheen A, Rietzschel E, Mangano A, Panier JP, Ducobu J, Langlois M, Balligand JL, Legat P, Blaton V, Muls E, Van Gaal L, Sokal E, Rooman R, Carpentier Y, De Backer G, Heller FR.

Atherosclerosis. 2011 Oct;218(2):272-80. doi: 10.1016/j.atherosclerosis.2011.06.016. Epub 2011 Jun 17. Review.

2.

Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.

Besseling J, Kindt I, Hof M, Kastelein JJ, Hutten BA, Hovingh GK.

Atherosclerosis. 2014 Mar;233(1):219-23. doi: 10.1016/j.atherosclerosis.2013.12.020. Epub 2014 Jan 11.

3.

Guidelines for the management of familial hypercholesterolemia.

Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K, Wakatsuki A, Ishibashi S, Yamashita S.

J Atheroscler Thromb. 2012;19(12):1043-60. Epub 2012 Oct 25.

4.

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Steinhagen-Thiessen E, Stroes ES, Taskinen MR, Tybjærg-Hansen A, Wiklund O; European Atherosclerosis Society Consensus Panel..

Eur Heart J. 2015 Sep 21;36(36):2425-37. doi: 10.1093/eurheartj/ehv157. Epub 2015 May 25. Review.

5.

Dutch Lipid Clinic Network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population.

Séguro F, Bongard V, Bérard E, Taraszkiewicz D, Ruidavets JB, Ferrières J.

Arch Cardiovasc Dis. 2015 Oct;108(10):511-8. doi: 10.1016/j.acvd.2015.04.003.

6.

[Diagnosis and treatment of familial hypercholesterolemia in Spain: Consensus document].

Mata P, Alonso R, Ruiz A, Gonzalez-Juanatey JR, Badimón L, Díaz-Díaz JL, Muñoz MT, Muñiz O, Galve E, Irigoyen L, Fuentes-Jiménez F, Dalmau J, Pérez-Jiménez F.

Semergen. 2015 Jan-Feb;41(1):24-33. doi: 10.1016/j.semerg.2014.05.001. Epub 2014 Jul 17. Spanish.

PMID:
25042971
7.

Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.

Vishwanath R, Hemphill LC.

J Clin Lipidol. 2014 Jan-Feb;8(1):18-28. doi: 10.1016/j.jacl.2013.11.002. Epub 2013 Nov 8.

PMID:
24528684
8.
9.

Two novel mutations in exon 3 and 4 of low density lipoprotein (LDL) receptor gene in patients with heterozygous familial hypercholesterolemia.

Khan SP, Ghani R, Ahmed KZ, Yaqoob Z.

J Coll Physicians Surg Pak. 2011 Jul;21(7):403-6. doi: 07.2011/JCPSP.402406.

PMID:
21777527
10.
11.

The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia.

Guardamagna O, Restagno G, Rolfo E, Pederiva C, Martini S, Abello F, Baracco V, Pisciotta L, Pino E, Calandra S, Bertolini S.

J Pediatr. 2009 Aug;155(2):199-204.e2. doi: 10.1016/j.jpeds.2009.02.022. Epub 2009 May 15.

PMID:
19446849
12.

Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations.

Torres AL, Moorjani S, Vohl MC, Gagné C, Lamarche B, Brun LD, Lupien PJ, Després JP.

Atherosclerosis. 1996 Sep 27;126(1):163-71.

PMID:
8879444
13.

The detection of heterozygous familial hypercholesterolemia in Ireland.

O'Kane MJ, Menown IB, Graham I, Maher V, Tomkin G, Nicholls P, Graham C.

Adv Ther. 2012 May;29(5):456-63. doi: 10.1007/s12325-012-0021-0. Epub 2012 May 17.

PMID:
22610724
14.

Heterozygous familial hypercholesterolemia in Hong Kong Chinese. Study of 252 cases.

Hu M, Lan W, Lam CW, Mak YT, Pang CP, Tomlinson B.

Int J Cardiol. 2013 Aug 10;167(3):762-7. doi: 10.1016/j.ijcard.2012.03.048. Epub 2012 Mar 30.

PMID:
22464486
15.

The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.

Jensen HK.

Dan Med Bull. 2002 Nov;49(4):318-45. Review.

PMID:
12553167
16.

[Heterozygous familial hypercholesterolemia].

Özcan ÖU, Güleç S.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 2:10-8. Review. Turkish.

17.

[Diagnosis and treatment of familial hypercholesterolemia in Spain: consensus document].

Mata P, Alonso R, Ruiz A, Gonzalez-Juanatey JR, Badimón L, Díaz-Díaz JL, Muñoz MT, Muñiz O, Galve E, Irigoyen L, Fuentes-Jiménez F, Dalmau J, Pérez-Jiménez F; otros colaboradores..

Aten Primaria. 2015 Jan;47(1):56-65. doi: 10.1016/j.aprim.2013.12.015. Epub 2014 Apr 3. Spanish.

18.
19.

Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia.

Santos PC, Morgan AC, Jannes CE, Turolla L, Krieger JE, Santos RD, Pereira AC.

Atherosclerosis. 2014 Mar;233(1):206-10. doi: 10.1016/j.atherosclerosis.2013.12.028. Epub 2014 Jan 4.

PMID:
24529145
20.

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.

Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M.

Circulation. 2012 Nov 6;126(19):2283-92. doi: 10.1161/CIRCULATIONAHA.112.104125. Epub 2012 Oct 11.

Supplemental Content

Support Center